Glenmark Pharmaceuticals reported a 35.1% revenue growth year-on-year for Q3 FY2025, with a PAT of Rs. 3,480 Mn and an EBITDA margin of 17.7%. The company highlighted strong growth in its India and European businesses while mentioning ongoing developments in its North America and dermatology portfolios.